CO6801773A2 - Espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 - Google Patents
Espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2Info
- Publication number
- CO6801773A2 CO6801773A2 CO13267226A CO13267226A CO6801773A2 CO 6801773 A2 CO6801773 A2 CO 6801773A2 CO 13267226 A CO13267226 A CO 13267226A CO 13267226 A CO13267226 A CO 13267226A CO 6801773 A2 CO6801773 A2 CO 6801773A2
- Authority
- CO
- Colombia
- Prior art keywords
- spiro
- oxacins
- oxacepins
- bace2
- bace1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11167835 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6801773A2 true CO6801773A2 (es) | 2013-11-29 |
Family
ID=46177417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13267226A CO6801773A2 (es) | 2011-05-27 | 2013-11-13 | Espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9079919B2 (es) |
| EP (1) | EP2714697B1 (es) |
| JP (1) | JP2014515382A (es) |
| KR (1) | KR20140048137A (es) |
| CN (1) | CN103596961B (es) |
| AU (1) | AU2012264875B2 (es) |
| BR (1) | BR112013030281A2 (es) |
| CA (1) | CA2833813A1 (es) |
| CL (1) | CL2013003372A1 (es) |
| CO (1) | CO6801773A2 (es) |
| CR (1) | CR20130580A (es) |
| EA (1) | EA024286B1 (es) |
| EC (1) | ECSP13013048A (es) |
| ES (1) | ES2600636T3 (es) |
| IL (1) | IL229334A (es) |
| MA (1) | MA35191B1 (es) |
| MX (1) | MX2013013910A (es) |
| PE (1) | PE20141205A1 (es) |
| SG (1) | SG194835A1 (es) |
| UA (1) | UA111847C2 (es) |
| WO (1) | WO2012163790A1 (es) |
| ZA (1) | ZA201308395B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103936690B (zh) | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
| KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
| US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
| US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
| AU2010328975B2 (en) | 2009-12-11 | 2015-01-22 | Shionogi & Co. Ltd. | Oxazine derivative |
| AU2011321427A1 (en) | 2010-10-29 | 2013-05-02 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| WO2012057247A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| CA2844988A1 (en) | 2011-08-22 | 2013-02-28 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono- and dioxides as bace inhibitors, compositions, and their use |
| BR112014029597A2 (pt) | 2012-05-30 | 2017-11-07 | Comentis Inc | compostos de cromano |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US9580396B2 (en) | 2012-12-21 | 2017-02-28 | Merck Sharp & Dohme Corp. | C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use |
| TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 |
| KR20150124985A (ko) | 2013-03-08 | 2015-11-06 | 암젠 인크 | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 |
| EP3043802B1 (en) | 2013-09-13 | 2018-04-18 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
| AR102202A1 (es) | 2014-10-07 | 2017-02-08 | Astrazeneca Ab | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
| WO2016150785A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003220483A1 (en) | 2002-05-09 | 2003-11-11 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| SV2006002232A (es) * | 2004-09-21 | 2006-05-25 | Lilly Co Eli | Inhibidores bace ref. x-16940 |
| ATE550338T1 (de) * | 2005-07-18 | 2012-04-15 | Merck Sharp & Dohme | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit |
| CN103936690B (zh) * | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
| AU2007293416A1 (en) | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| WO2010013794A1 (en) * | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| EP2324032B1 (en) | 2008-08-19 | 2014-10-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| US8703785B2 (en) * | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
| WO2010073078A2 (en) | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
| US8461160B2 (en) * | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US8188079B2 (en) * | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| EP2500344A4 (en) * | 2009-11-13 | 2013-05-01 | Shionogi & Co | AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION |
| US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| WO2011123674A1 (en) * | 2010-03-31 | 2011-10-06 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| JP2012250933A (ja) * | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
-
2012
- 2012-05-21 US US13/476,094 patent/US9079919B2/en not_active Expired - Fee Related
- 2012-05-24 EA EA201391752A patent/EA024286B1/ru not_active IP Right Cessation
- 2012-05-24 SG SG2013082607A patent/SG194835A1/en unknown
- 2012-05-24 EP EP12724116.4A patent/EP2714697B1/en not_active Not-in-force
- 2012-05-24 PE PE2013002577A patent/PE20141205A1/es not_active Application Discontinuation
- 2012-05-24 WO PCT/EP2012/059688 patent/WO2012163790A1/en active Application Filing
- 2012-05-24 UA UAA201315118A patent/UA111847C2/uk unknown
- 2012-05-24 BR BR112013030281A patent/BR112013030281A2/pt not_active IP Right Cessation
- 2012-05-24 JP JP2014513129A patent/JP2014515382A/ja active Pending
- 2012-05-24 MX MX2013013910A patent/MX2013013910A/es unknown
- 2012-05-24 AU AU2012264875A patent/AU2012264875B2/en not_active Expired - Fee Related
- 2012-05-24 KR KR1020137033959A patent/KR20140048137A/ko not_active Application Discontinuation
- 2012-05-24 CN CN201280025801.2A patent/CN103596961B/zh not_active Expired - Fee Related
- 2012-05-24 ES ES12724116.4T patent/ES2600636T3/es active Active
- 2012-05-24 CA CA2833813A patent/CA2833813A1/en not_active Abandoned
-
2013
- 2013-11-07 ZA ZA2013/08395A patent/ZA201308395B/en unknown
- 2013-11-07 CR CR20130580A patent/CR20130580A/es unknown
- 2013-11-07 IL IL229334A patent/IL229334A/en not_active IP Right Cessation
- 2013-11-13 CO CO13267226A patent/CO6801773A2/es not_active Application Discontinuation
- 2013-11-25 EC ECSP13013048 patent/ECSP13013048A/es unknown
- 2013-11-25 CL CL2013003372A patent/CL2013003372A1/es unknown
- 2013-12-18 MA MA36582A patent/MA35191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2833813A1 (en) | 2012-12-06 |
| JP2014515382A (ja) | 2014-06-30 |
| MA35191B1 (fr) | 2014-06-02 |
| AU2012264875A1 (en) | 2013-10-31 |
| EA201391752A1 (ru) | 2014-04-30 |
| IL229334A0 (en) | 2014-01-30 |
| KR20140048137A (ko) | 2014-04-23 |
| WO2012163790A1 (en) | 2012-12-06 |
| ECSP13013048A (es) | 2014-01-31 |
| US20120302549A1 (en) | 2012-11-29 |
| SG194835A1 (en) | 2013-12-30 |
| CN103596961B (zh) | 2016-09-28 |
| AU2012264875B2 (en) | 2017-04-27 |
| BR112013030281A2 (pt) | 2016-11-29 |
| CR20130580A (es) | 2013-12-09 |
| MX2013013910A (es) | 2014-01-24 |
| NZ616817A (en) | 2015-12-24 |
| EP2714697B1 (en) | 2016-08-31 |
| CN103596961A (zh) | 2014-02-19 |
| ES2600636T3 (es) | 2017-02-10 |
| CL2013003372A1 (es) | 2014-07-25 |
| US9079919B2 (en) | 2015-07-14 |
| ZA201308395B (en) | 2014-07-30 |
| IL229334A (en) | 2017-02-28 |
| EP2714697A1 (en) | 2014-04-09 |
| PE20141205A1 (es) | 2014-09-22 |
| UA111847C2 (uk) | 2016-06-24 |
| EA024286B1 (ru) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6801773A2 (es) | Espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| CO6801766A2 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| CO7071122A2 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CO6811854A2 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| BR112013016360A2 (pt) | 1,4 oxazinas como inibidores de bace1 e/ou bace2 | |
| BR112013014610A2 (pt) | 1,4 oxazinas como inibidores de bace1 e/ou bace2 | |
| BR112013020019A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2. | |
| CO6940411A2 (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
| CO6880072A2 (es) | Compuestos de n-tio-antranilamida y sus usos como plaguicidas | |
| AP4029A (en) | Inhibitors of beta-secretase | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| DK2846827T3 (da) | Biofilmdesintegration med plyss2-lysin | |
| CO6862145A2 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| BR112014000022A2 (pt) | 1-3-tiazepinas ciclopropil-fundidas como inibidores de bace 1 e/ou bace 2 | |
| IL236138A0 (en) | Difluoro-hexahydro-cyclopentaoxazinil and difluoro-hexahydro-benzooxazinil as BACE1 inhibitors | |
| CO6880071A2 (es) | Compuestos de antranilamida y sus usos como plaguicidas | |
| IL236963A0 (en) | beta-secretase inhibitors | |
| CO6880073A2 (es) | Compuestos de antranilamida y sus usos como plaguicidas | |
| DK2802537T3 (da) | Formaldehyd-frie lignin-amin-koaguleringsmidler | |
| ITRM20120473A1 (it) | Use of glycerophosphoinositols for the treatment of septic shock | |
| ZA201309171B (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
| CO6852098A2 (es) | Uso de tetracianoditiínas como fungicidas | |
| TH1401002835B (th) | ผลิตภัณฑ์ซึมซับและวิธีการผลิตสำหรับสิ่งนี้ | |
| ES1076361Y (es) | Anfora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |